Free Trial
NASDAQ:FBIOP

Fortress Biotech (FBIOP) Stock Price, News & Analysis

Fortress Biotech logo
$6.51 -0.15 (-2.25%)
Closing price 05/22/2025 03:57 PM Eastern
Extended Trading
$6.50 -0.01 (-0.22%)
As of 05/22/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fortress Biotech Stock (NASDAQ:FBIOP)

Key Stats

Today's Range
$6.48
$6.65
50-Day Range
$5.08
$6.82
52-Week Range
$4.72
$17.45
Volume
7,404 shs
Average Volume
17,327 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
35.94%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Receive FBIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIOP Stock News Headlines

7 Tiny “Trump Stocks” Poised for Large Moves
7 Cheap and Good Stocks to Buy Now 💰 Discover 7 massively discounted stocks ready for growth. This free report features companies like Stock #1, a niche AI leader in voice recognition technology, and Stock #6, an energy drink company rapidly expanding across major retailers.
See More Headlines

FBIOP Stock Analysis - Frequently Asked Questions

Fortress Biotech's stock was trading at $6.65 at the beginning of 2025. Since then, FBIOP stock has decreased by 2.1% and is now trading at $6.51.
View the best growth stocks for 2025 here
.

Shares of FBIOP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/23/2025
Next Earnings (Estimated)
8/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FBIOP
Fax
N/A
Employees
170
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$57.78 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:FBIOP) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners